

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

1-24. (Canceled)

25. (Withdrawn) A method for treating a wound and/or improving wound healing wherein a therapeutically effective amount of a pharmaceutical composition comprising a substance that inhibits a pro-inflammatory cytokine is administered to a patient in need of said treatment.

26. (Withdrawn) A method according to claim 25, wherein said pro-inflammatory cytokine is selected from the group consisting of TNF, IL-1, IL-6, IL-8, IL-12, IL-15, IL-17, IL-18, GM-CSF, M-CSF, MCP-1, MIP-1, RANTES, ENA-78, OSM, FGF, PDGF, and VEGF.

27. (Withdrawn) A method according to claim 25, wherein said pro-inflammatory cytokine is selected from the group consisting of TNF and IL-1.

28. (Withdrawn) A method according to claim 25, for treatment of posttraumatic tissue injury.

29. (Withdrawn) A method according to claim 28, wherein said posttraumatic tissue injury is caused by surgery.

30. (Withdrawn) A method according to claim 25, for treatment of thermic injury.

31. (Withdrawn) A method according to claim 25, for treatment of a wound resulting from a metabolic process due to reduced nutritional supply.

32. (Withdrawn) A method according to claim 31, for treatment of a diabetic ulcer, a leg ulcer, a decubitus ulcer or a gastric ulcer.

33. (Withdrawn) A method according to claim 25, for treatment of a wound resulting from exposure to a toxic compound.

34. (Withdrawn) A method according to claim 25, wherein said substance is a monoclonal antibody.

35. (Withdrawn) A method according to claim 34, wherein said substance is selected from the group consisting of infliximab, CDP-571, D2E7 and CDP-870.

36. (Withdrawn) A method according to claim 25, wherein said substance is a soluble cytokine receptor.

37. (Withdrawn) A method according to claim 36, wherein said substance is etanercept.

38. (Withdrawn) A method according to claim 25, wherein said substance is a receptor antagonist.

39. (Withdrawn) A method according to claim 25, wherein said substance is an antisense oligonucleotide.

40. (Withdrawn) A method according to claim 25, wherein said substance is an MMP inhibitor selected from the group consisting of tetracyclines, chemically modified tetracyclines, Prinomastat, Batimastat, Marimastat, KB-R7785, TIMP-1, TIMP-2, adTIMP-1, and adTIMP-2.

41. (Withdrawn) A method according to claim 25, wherein said substance is an quinolones selected from the group consisting of Norfloxacin, Levofloxacin, Enoxacin, Sparfloxacin, Temafloxacin, Moxifloxacin, Gatifloxacin, Gemifloxacin,

Grepafloxacin, Trovafloxacin, Ofloxacin, Ciprofloxacin, Pefloxacin, Lomefloxacin, and Temafloxacin.

42. (Withdrawn) A method according to claim 25, wherein said substance is a thalidomide derivate selected from the group consisting of CC-1088, CDC-501, CDC-801 and Linomide.

43. (Withdrawn) A method according to claim 25, wherein said substance is selected from the group consisting of prostaglandins, phosphodiesterase I, II, III, IV, and V-inhibitors, cyclosporin, pentoxifyllin derivates, hydroxamic acid derivates, melanin and melancortin agonists, and lazaroids.

44. (Withdrawn) A method according to claim 25, wherein said substance is a specific IL-1 $\gamma$  and/or IL-1 $\beta$  blocking substance.

45. (Withdrawn) A method according to claim 25, wherein said substance is a non-specific IL-1 $\gamma$  and/or IL-1 $\beta$  blocking substance.

46. (Currently Amended) A method for treating a wound and/or improving wound healing wherein a therapeutically effective amount of a pharmaceutical composition comprising a peptide derived from amino acid 12 to amino acid 40 of human lactoferrin ~~a peptide derived or derivable from lactoferrin~~ that inhibits a pro-inflammatory cytokine is administered to a patient in need of said treatment.

47. (Withdrawn) A method according to claim 25, wherein said substance is locally administered.

48. (Withdrawn) A method according to claim 25, wherein said substance is systemically administered.